Various studies looking at the impact of steroids, are now being published. They show that, overall, children with Duchenne who are treated with steroids, stay walking for longer than those who are not treated with steroids. The effect is variable from child to child, and the children who respond well to steroids, also seem to develop other complications less frequently. They develop breathing difficulties later, and have fewer problems with their spines. There may also be a positive effect on the heart muscle.

Prednisolone and Deflazacort are the steroids most often prescribed for Duchenne.

However, there can be important side effects, the worst of which are significant growth delay, cushingoid (puffy face), delayed puberty and a weakening of the bones. There is ongoing research to establish the most effective dose and regimens for steroids, to enable clinicians to minimise the side effects and maximise the benefits.

Potential alternatives to steroids

ReveraGen Biopharma, a US pharmaceutical company, is developing a new steroidal drug called Vamorolone (previously VBP15) which has the potential to better balance the benefit and side effects than the more traditional steroids. A successful Phase 1 study in adult volunteers was funded by Duchenne Children’s Trust, Joining Jack and the MDA (USA).

As of September 2016 ReveraGen Biopharma has begun recruiting patients for its Phase 2a open label study of Vamorolone. The trial will be recruiting patients who haven’t yet started steroids, between the ages of 4-7, and is recruiting in the UK, United States, Canada, Israel, Sweden and Australia.

For more information please visit: http://vision-dmd.info/2a-trial-information/

CAT-1004, Edasalonexent was being developed by the US company Catabasis, but in November 2020, results from their Phase 3 trial showed that it did not meet either its primary or secondary endpoint, meaning that it was not shown to be effective. 

For more information please visit: https://ir.catabasis.com/news-releases/news-release-details/catabasis-pharmaceuticals-announces-top-line-results-phase-3